UNSPSC 51384616: Pirazolac

This classification denotes a nonsteroidal antiinflammatory drug with the molecular formula C17H12ClFN2O2, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier FWY2578LP5, chemically known as 1h-pyrazole-3-acetic acid, 4-(4-chlorophenyl)-1-(4-fluorophenyl)- but generally known as pirazolac, which bears US NIH Compound Identifier 51222. European Medicines Agency schedules Pirazolac in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB09898MIG.

UNSPSC 51384616 Pirazolac (Commodity) represents pharmaceutical products procured by state and local health agencies, though recent solicitation activity under this code shows limited alignment with the nominal commodity name. Seminole County, Florida released an IFB in June 2026 for naloxone and drug deactivation systems, a public-health-focused procurement that does not correspond to pirazolac (an anti-inflammatory medication) but was tagged under this code. State and local buyers using this code tier appear limited to specialized health departments and county public-health divisions rather than broader municipal or educational procurement offices. The work solicited emphasizes emergency medical supplies and harm-reduction equipment delivered on recurring schedules, with compliance requirements including drug-free workplace certification, E-Verify authorization, and federal audit readiness when FEMA funding is involved.

The Seminole County IFB (IFB60459723LAS, due July 26, 2023) represents the primary visible recent activity under this code. The procurement calls for 1,900 units of naloxone and 800 safe drug deactivation systems annually on a two-year initial term with one-year renewal option, with quarterly deliveries to a county health facility in Sanford, Florida. Bidders must include all shipping and delivery costs in their proposals and meet insurance, bonding, and federal-compliance obligations. The code shows little recent activity beyond this Florida solicitation, suggesting either narrow demand among state and local issuers or systematic miscoding of pharmaceutical procurements across the sector. Firms pursuing this code should verify alignment with actual health-agency acquisition patterns in target states rather than relying on the commodity name alone.